ARAY$0.1439-2.77%
Accuray Inc.
Sector: Surgical & Medical Instruments & ApparatusIndustry: Medical - DevicesCountry: USExchange: Nasdaq
Mkt Cap:$17.19M
Float & O/S:
Inst Own:
DilutionScan read 22 of ACCURAY INC's SEC filings and found 9 warrant series, 2 convertibles, 3 shelf registrations and 3 completed offerings on file for ARAY. The latest dilution event on file is a registration statement on Sep 11, 2026. Analysis updated Sep 28, 2026.
Signal8 Summary
ARAY
Distressed micro-cap facing reverse split, heavy dilution
Snapshot
Accuray is a radiation-therapy equipment maker whose revenue shrank 12% to $401.9M in fiscal 2026 and posted a $49.2M net loss.
What's Happening Right Now
- : On Oct 6, 2026, stockholders approved a TCW-led rescue package: a $40M debt-for-preferred swap, a $15M equity investment, covenant relief through 2027, and a reverse split of 1-for-15 to 1-for-40.
- : A September 2026 prospectus registered resale of 6.8M warrant shares tied to an $18.25M loan draw, with total lender warrants covering roughly 44% of shares outstanding, many deeply in the money at a $0.01 strike.
- : On Sept 11, 2026, Accuray and RaySearch signed a collaboration integrating RayStation software with Accuray's platforms to advance its online adaptive radiation therapy capabilities.
- : Registered 6.83M shares for sale on Form S-3.
- : Fiscal 2026 revenue fell 12% to $401.9M with a $49.2M net loss; Q4 orders dropped sharply and backlog fell 27%, and management withdrew fiscal 2027 guidance.
- : Nasdaq moved Accuray down to the Capital Market tier effective Aug 6, 2026, giving the company until Feb 1, 2027 to get its share price back above $1 or face delisting.
- : Issued warrants over 15.25M shares.
- : Closed an offering. Proceeds are not disclosed in the filings reviewed, with warrants over 6.83M shares.
